Table 2.

Summary of treatment efficacy assessed by the investigator

Responses	All patients (n = 30)
CR, n (%)	1 (3.3)
PR, n (%)	23 (76.7)
SD, n (%)	4 (13.3)
PD, n (%)	1 (3.3)
NE, n (%)	1 (3.3)
ORR, n (%)	24 (80.0) (95% CI: 61.4–92.3)
DCR, n (%)	28 (93.3) (95% CI: 77.9–99.2)
Median DoR	11 months (95% CI: 7.8–15 months)
Median TTR	2.1 months (95% CI: 2.07-2.13months)
Median PFS	10.2 months (95% CI: 9.3–16.8 months)
Median OS	22.5 months (95% CI: 15.6 months–29.3 months)
1-year OS (%)	76.7 (95% CI: 62.9–93.4)
1-year PFS (%)	41.4 (95% CI: 26.8–63.8)
2-year OS (%)	49.8 (95% CI: 34.7–71.4)

CR complete response, PR partial response, SD stable disease, PD progression disease, NE not evaluable, ORR objective response rate, DCR disease control rate, DoR duration of response, TTR time to response, PFS progression-free survival, OS overall survival, CI confidence interval